Immunotherapy with dendritic cells for prostate cancer
/in International Publications, Prostate CancerLaboratory and clinical basis for hyperthermia as a component of intracavitary chemotherapy
/in Hyperthermia, International Publications, Malignant Pleural MesotheliomaBenefits of superficial hyperthermia treatment planning: five case studies
/in Breast Cancer, Hyperthermia, International Publications, Malignant MelanomaConformal radiotherapy plus local hyperthermia in patients affected by locally advanced high risk prostate cancer: preliminary results of a prospective phase II study
/in Hyperthermia, International Publications, Prostate CancerDendritic cell vaccination
/in Breast Cancer, Colorectal Cancer, Hypernephroma, International Publications, Malignant Melanoma, Prostate CancerRole of tumor endothelium in CD4+ CD25+ regulatory T cell infiltration of human pancreatic carcinoma
/in International Publications, Pancreatic CancerEnhanced antitumour immunity by combined use of temozolomide and TAT-survivin pulsed dendritic cells in a murine glioma
/in Glioblastoma, International PublicationsDevelopment of vaccines for high-risk ductal carcinoma in situ of the breast
/in Breast Cancer, International Publications[State of the art about new therapeutic vaccines in prostate cancer: dendritic cells, engineered tumor cells and recombinant virus]
/in International Publications, Prostate Cancer
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer